Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Wet Age-related Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
65
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
Conditions
Age-Related Macular Degeneration
Interventions
Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF)
Drug · Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Conditions
Macular Degeneration
Interventions
Abicipar Pegol, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Beverly Hills, California • Miami, Florida • Portsmouth, New Hampshire
Conditions
Retinal Vasculitis
Interventions
aflibercept 2mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
290,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Conditions
Wet Macular Degeneration
Interventions
BI 836880
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • New York, New York • Eugene, Oregon + 4 more
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Lucentis (Ranibizumab)
Drug
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Miami, Florida
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Intravitreal Aflibercept Injection 2mg
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Age-related Macular Degeneration (AMD)
Interventions
No intervention.
Device
Lead sponsor
iHealthScreen Inc
Industry
Eligibility
50 Years and older
Enrollment
1,076 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Richmond Hill, New York
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD
Interventions
VOY-101
Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Scottsdale, Arizona • Encino, California • Sacramento, California + 4 more
Conditions
Age-Related (Dry) Macular Degeneration
Interventions
Retina imaging device (MSI-120) and AI (DeepMSI AI)
Device
Lead sponsor
AI-Spectral
Industry
Eligibility
40 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Woodbridge, New Jersey
Conditions
Advanced Age-related Macular Degeneration
Interventions
LFG316
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more
Conditions
Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
12
States / cities
Davis, California • Palo Alto, California • Sacramento, California + 7 more
Conditions
Macular Degeneration
Interventions
abicipar pegol, ranibizumab, sham procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab, bevacizumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
59
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
Conditions
Macular Degeneration
Interventions
Epi-Rad90™ Ophthalmic System, ranibizumab
Device · Drug
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
65 Years and older
Enrollment
250 participants
Timeline
2023 – 2027
U.S. locations
10
States / cities
Glendale, California • Mountain View, California • Carmel, Indiana + 7 more
Conditions
Exudative Macular Degeneration
Interventions
Aflibercept
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Conditions
Non-exudative Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Terminated No phase listed Observational Accepts healthy volunteers

Visual Function Tests in Age-related Macular Degeneration

NCT03275753
Conditions
Age Related Macular Degeneration
Interventions
Visual Function Tests
Other
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts